Symbols / ARGX Stock $787.31 -2.51% argenx SE

Healthcare • Biotechnology • Netherlands • NMS
ARGX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NMS · Netherlands
Market Cap 49.20B
Enterprise Value 44.47B
Income 1.49B
Sales 4.74B
FCF (ttm) —
Book/sh 4.73
Cash/sh 71.54
Employees 1,863
Insider 10d —
IPO May 18, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 34.98
Forward P/E 23.83
PEG 1.29
P/S 10.37
P/B 166.33
P/C —
EV/EBITDA 33.73
EV/Sales 9.38
Quick Ratio —
Current Ratio —
Debt/Eq 0.64
LT Debt/Eq —
EPS (ttm) 22.51
EPS next Y 33.04
EPS Growth 114.00%
Revenue Growth 62.60%
EPS Gr Q/Q 116.00%
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA —
ROE —
ROIC —
Gross Margin 58.11%
Oper. Margin 30.01%
Profit Margin 31.40%
Shs Outstand 62.19M
Shs Float 61.98M
Insider Own 0.01%
Instit Own 50.88%
Short Float 3.67%
Short Ratio 6.97
Short Interest 2.28M
52W High 934.62
vs 52W High -15.76%
52W Low 510.06
vs 52W Low 54.36%
Beta -0.06
Impl. Vol. 0.39%
Rel Volume 1.35
Avg Volume 337.58K
Volume 455.71K
Target (mean) $1,037.19
Tgt Median $1,031.75
Tgt Low $702.38
Tgt High $1,252.13
# Analysts 21
Recom Strong_buy
Prev Close $807.55
Price $787.31
Change -2.51%
About

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1037.19
Mean price target
2. Current target
$787.31
Latest analyst target
3. DCF / Fair value
$337.65
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$787.31
Low
$702.38
High
$1252.13
Mean
$1037.19

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-02 main Oppenheimer Outperform → Outperform $1014
2026-03-09 reit Wedbush Outperform → Outperform $1000
2026-02-27 main RBC Capital Outperform → Outperform $890
2026-02-27 main Wells Fargo Overweight → Overweight $1247
2026-02-27 main Citizens Market Outperform → Market Outperform $944
2026-02-27 main Guggenheim Buy → Buy $1120
2026-02-27 main Baird Neutral → Neutral $867
2026-02-27 main HC Wainwright & Co. Buy → Buy $940
2026-01-20 main Wells Fargo Overweight → Overweight $1317
2026-01-14 reit Wedbush Outperform → Outperform $1000
2026-01-08 main Citigroup Buy → Buy $1091
2026-01-08 main Truist Securities Buy → Buy $1030
2025-12-18 down Baird Outperform → Neutral $858
2025-12-17 main RBC Capital Outperform → Outperform $925
2025-12-16 main Wells Fargo Overweight → Overweight $1264
2025-12-11 main Wells Fargo Overweight → Overweight $1316
2025-12-11 main Stifel Buy → Buy $1248
2025-12-08 main JP Morgan Overweight → Overweight $1100
2025-12-04 main Morgan Stanley Overweight → Overweight $1110
2025-11-24 down Wolfe Research Outperform → Peer Perform —
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4,153.48
+89.64%
2,190.23
+78.60%
1,226.32
+198.56%
410.75
Operating Revenue
4,151.32
+89.91%
2,185.88
+83.57%
1,190.78
+189.91%
410.75
Cost Of Revenue
450.67
+98.28%
227.29
+92.89%
117.83
+300.38%
29.43
Reconciled Cost Of Revenue
429.64
+101.79%
212.91
+2293.87%
8.89
-69.78%
29.43
Gross Profit
3,702.82
+88.64%
1,962.94
+77.08%
1,108.48
+190.70%
381.31
Operating Expense
2,648.20
+33.69%
1,980.79
+29.54%
1,529.12
+38.35%
1,105.23
Research And Development
1,364.13
+38.71%
983.42
+14.42%
859.49
+29.57%
663.37
Selling General And Administration
1,359.98
+29.25%
1,052.19
+48.29%
709.54
+50.99%
469.92
Selling And Marketing Expense
429.19
+31.38%
326.68
+53.73%
212.50
+83.27%
115.95
General And Administrative Expense
930.79
+28.29%
725.51
+45.97%
497.04
+40.42%
353.97
Salaries And Wages
500.53
+17.80%
424.92
+40.22%
303.03
+29.09%
234.74
Other Gand A
414.22
+48.09%
279.70
+53.06%
182.74
+66.73%
109.60
Other Operating Expenses
-82.99
-43.15%
-57.97
-37.13%
-42.28
-39.70%
-30.26
Total Expenses
3,098.87
+40.34%
2,208.07
+34.07%
1,646.95
+45.15%
1,134.66
Operating Income
1,054.62
+6010.19%
-17.84
+95.76%
-420.64
+41.89%
-723.92
Total Operating Income As Reported
1,053.81
+4966.57%
-21.65
+94.91%
-425.05
+40.99%
-720.34
EBITDA
1,310.79
+1146.34%
105.17
+154.70%
-192.28
+69.13%
-622.78
Normalized EBITDA
1,233.42
+724.76%
149.55
+172.47%
-206.36
+65.35%
-595.51
Reconciled Depreciation
28.10
+60.34%
17.53
-84.25%
111.31
+6.68%
104.34
EBIT
1,282.69
+1363.52%
87.64
+128.87%
-303.59
+58.25%
-727.12
Total Unusual Items
77.37
+274.35%
-44.38
-415.33%
14.07
+151.62%
-27.27
Total Unusual Items Excluding Goodwill
77.37
+274.35%
-44.38
-415.33%
14.07
+151.62%
-27.27
Net Income
1,292.04
+55.10%
833.04
+382.34%
-295.05
+58.42%
-709.59
Pretax Income
1,278.61
+1401.06%
85.18
+127.97%
-304.50
+58.25%
-729.31
Net Non Operating Interest Income Expense
159.01
+2.56%
155.04
+45.61%
106.48
+372.24%
22.55
Interest Expense Non Operating
4.08
+65.67%
2.46
+171.96%
0.91
-58.69%
2.19
Net Interest Income
159.01
+2.56%
155.04
+45.61%
106.48
+372.24%
22.55
Interest Expense
4.08
+65.67%
2.46
+171.96%
0.91
-58.69%
2.19
Interest Income Non Operating
163.09
+3.54%
157.51
+46.68%
107.39
+334.04%
24.74
Interest Income
163.09
+3.54%
157.51
+46.68%
107.39
+334.04%
24.74
Other Income Expense
64.98
+224.92%
-52.02
-638.41%
9.66
+134.58%
-27.94
Gain On Sale Of Security
77.37
+274.35%
-44.38
-415.33%
14.07
+151.62%
-27.27
Tax Provision
-13.43
+98.20%
-747.86
-7819.73%
-9.44
+52.11%
-19.72
Tax Rate For Calcs
0.00
+0.00%
0.00
+577.16%
0.00
+14.69%
0.00
Tax Effect Of Unusual Items
16.25
+274.35%
-9.32
-2235.32%
0.44
+159.20%
-0.74
Net Income Including Noncontrolling Interests
1,292.04
+55.10%
833.04
+382.34%
-295.05
+58.42%
-709.59
Net Income From Continuing Operation Net Minority Interest
1,292.04
+55.10%
833.04
+382.34%
-295.05
+58.42%
-709.59
Net Income From Continuing And Discontinued Operation
1,292.04
+55.10%
833.04
+382.34%
-295.05
+58.42%
-709.59
Net Income Continuous Operations
1,292.04
+55.10%
833.04
+382.34%
-295.05
+58.42%
-709.59
Normalized Income
1,230.91
+41.79%
868.10
+381.22%
-308.69
+54.81%
-683.07
Net Income Common Stockholders
1,292.04
+55.10%
833.04
+382.34%
-295.05
+58.42%
-709.59
Diluted EPS
19.57
+53.13%
12.78
+347.67%
-5.16
+60.46%
-13.05
Basic EPS
21.08
+51.44%
13.92
+369.77%
-5.16
+60.46%
-13.05
Basic Average Shares
61.30
+2.41%
59.86
+4.70%
57.17
+5.13%
54.38
Diluted Average Shares
66.03
+1.31%
65.18
+14.01%
57.17
+5.13%
54.38
Diluted NI Availto Com Stockholders
1,292.04
+55.10%
833.04
+382.34%
-295.05
+58.42%
-709.59
Depreciation Amortization Depletion Income Statement
7.08
+124.80%
3.15
+33.09%
2.37
+7.01%
2.21
Depreciation And Amortization In Income Statement
7.08
+124.80%
3.15
+33.09%
2.37
+7.01%
2.21
Earnings From Equity Interest
-12.39
-62.09%
-7.64
-73.29%
-4.41
-551.55%
-0.68
Other Taxes
—
—
—
-28.08
Rent And Landing Fees
16.04
-23.23%
20.89
+85.44%
11.26
+17.00%
9.63
Rent Expense Supplemental
16.04
-23.23%
20.89
+85.44%
11.26
+17.00%
9.63
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
8,682.70
+39.99%
6,202.52
+36.55%
4,542.46
+44.93%
3,134.26
Current Assets
6,899.10
+41.29%
4,883.10
+18.41%
4,123.74
+48.65%
2,774.20
Cash Cash Equivalents And Short Term Investments
4,440.04
+31.41%
3,378.83
+6.26%
3,179.84
+45.03%
2,192.55
Cash And Cash Equivalents
3,491.29
+132.76%
1,499.94
-26.79%
2,048.84
+155.87%
800.74
Cash Equivalents
2,541.11
+82.24%
1,394.41
-16.91%
1,678.10
+150.78%
669.15
Cash Financial
950.18
+800.41%
105.53
-71.54%
370.74
+181.74%
131.59
Other Short Term Investments
948.75
-49.50%
1,878.89
+66.13%
1,131.00
-18.74%
1,391.81
Receivables
1,657.06
+82.28%
909.10
+82.08%
499.27
+80.06%
277.27
Accounts Receivable
1,489.57
+82.16%
817.71
+95.63%
417.99
+73.28%
241.23
Other Receivables
10.83
+5.27%
10.29
+126.33%
4.55
+74.64%
2.60
Taxes Receivable
123.12
+201.14%
40.89
-35.72%
63.60
+209.88%
20.53
Accrued Interest Receivable
33.53
-16.61%
40.21
+206.37%
13.13
+1.61%
12.92
Inventory
473.53
+16.28%
407.23
+31.13%
310.55
+36.00%
228.35
Raw Materials
335.54
-0.68%
337.83
+40.27%
240.84
+91.07%
126.05
Work In Process
55.53
+110.70%
26.36
-44.01%
47.07
-27.60%
65.02
Finished Goods
82.45
+91.56%
43.04
+90.12%
22.64
-39.29%
37.29
Prepaid Assets
328.48
+74.77%
187.95
+40.18%
134.07
+76.36%
76.02
Other Current Assets
—
—
—
-0.00
Total Non Current Assets
1,783.59
+35.18%
1,319.42
+215.11%
418.72
+16.29%
360.06
Net PPE
48.25
+10.87%
43.52
+91.91%
22.68
+39.67%
16.23
Gross PPE
83.97
+15.48%
72.72
+60.34%
45.35
+32.29%
34.28
Accumulated Depreciation
-35.72
-22.34%
-29.20
-28.77%
-22.68
-25.64%
-18.05
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
46.91
-4.24%
48.99
+71.38%
28.59
+44.26%
19.82
Machinery Furniture Equipment
29.22
+43.08%
20.42
+41.38%
14.45
+18.99%
12.14
Other Properties
0.35
+0.00%
0.35
+0.00%
0.35
+0.00%
0.35
Leases
7.49
+153.26%
2.96
+49.72%
1.98
-0.30%
1.98
Goodwill And Other Intangible Assets
272.10
+49.96%
181.44
+44.89%
125.23
-28.40%
174.90
Other Intangible Assets
272.10
+49.96%
181.44
+44.89%
125.23
-28.40%
174.90
Investments And Advances
50.53
+1.68%
49.70
+5.39%
47.16
+16.49%
40.48
Long Term Equity Investment
3.38
-63.55%
9.27
-6.50%
9.91
+649.21%
1.32
Non Current Accounts Receivable
86.21
-9.11%
94.85
+23.66%
76.71
+61.53%
47.49
Non Current Deferred Assets
1,295.85
+40.20%
924.30
+850.82%
97.21
+22.71%
79.22
Non Current Deferred Taxes Assets
1,295.85
+40.20%
924.30
+850.82%
97.21
+22.71%
79.22
Non Current Prepaid Assets
25.81
+9.17%
23.64
-50.04%
47.33
0.00
Other Non Current Assets
4.84
+146.46%
1.96
-18.82%
2.42
+39.21%
1.74
Total Liabilities Net Minority Interest
1,359.61
+93.06%
704.24
+58.27%
444.95
+38.80%
320.56
Current Liabilities
1,320.19
+97.07%
669.92
+58.38%
422.99
+39.94%
302.28
Payables And Accrued Expenses
694.98
+86.78%
372.09
+39.12%
267.45
+37.13%
195.04
Payables
694.98
+86.78%
372.09
+39.12%
267.45
+37.13%
195.04
Accounts Payable
554.27
+61.96%
342.23
+39.37%
245.56
+30.12%
188.72
Other Payable
98.50
+497.95%
16.47
-6.21%
17.56
+459.01%
3.14
Current Accrued Expenses
—
—
55.79
+186.42%
19.48
Employee Benefits
3.09
+71.55%
1.80
+24.43%
1.45
+66.55%
0.87
Pensionand Other Post Retirement Benefit Plans Current
212.34
+40.79%
150.82
+58.58%
95.10
+12.77%
84.34
Total Tax Payable
42.21
+215.23%
13.39
+208.95%
4.33
+36.25%
3.18
Current Debt And Capital Lease Obligation
10.83
+65.82%
6.53
+40.62%
4.65
+35.97%
3.42
Current Capital Lease Obligation
10.83
+65.82%
6.53
+40.62%
4.65
+35.97%
3.42
Current Deferred Liabilities
—
—
—
0.00
Current Deferred Revenue
—
—
—
0.00
Other Current Liabilities
—
—
—
0.00
Total Non Current Liabilities Net Minority Interest
39.42
+14.85%
34.32
+56.31%
21.96
+20.09%
18.29
Long Term Debt And Capital Lease Obligation
36.33
+11.71%
32.52
+111.80%
15.35
+70.43%
9.01
Long Term Capital Lease Obligation
36.33
+11.71%
32.52
+111.80%
15.35
+70.43%
9.01
Non Current Deferred Liabilities
0.00
0.00
-100.00%
5.16
-38.67%
8.41
Non Current Deferred Revenue
—
—
—
0.00
Non Current Deferred Taxes Liabilities
0.00
0.00
-100.00%
5.16
-38.67%
8.41
Other Non Current Liabilities
—
—
—
-0.00
Stockholders Equity
7,323.09
+33.19%
5,498.28
+34.19%
4,097.51
+45.63%
2,813.70
Common Stock Equity
7,323.09
+33.19%
5,498.28
+34.19%
4,097.51
+45.63%
2,813.70
Capital Stock
7.35
+1.76%
7.23
+2.39%
7.06
+6.30%
6.64
Common Stock
7.35
+1.76%
7.23
+2.39%
7.06
+6.30%
6.64
Share Issued
61.88
+1.85%
60.76
+2.65%
59.19
+6.86%
55.40
Ordinary Shares Number
61.88
+1.85%
60.76
+2.65%
59.19
+6.86%
55.40
Additional Paid In Capital
6,186.55
+3.99%
5,948.92
+5.26%
5,651.50
+31.13%
4,309.88
Retained Earnings
-279.77
+82.20%
-1,571.80
+34.64%
-2,404.84
-13.98%
-2,109.79
Gains Losses Not Affecting Retained Earnings
73.59
+10.31%
66.71
-7.43%
72.07
+0.49%
71.72
Other Equity Adjustments
—
—
—
477.69
Total Equity Gross Minority Interest
7,323.09
+33.19%
5,498.28
+34.19%
4,097.51
+45.63%
2,813.70
Total Capitalization
7,323.09
+33.19%
5,498.28
+34.19%
4,097.51
+45.63%
2,813.70
Working Capital
5,578.92
+32.42%
4,213.19
+13.85%
3,700.74
+49.71%
2,471.92
Invested Capital
7,323.09
+33.19%
5,498.28
+34.19%
4,097.51
+45.63%
2,813.70
Total Debt
47.16
+20.76%
39.05
+95.27%
20.00
+60.95%
12.43
Capital Lease Obligations
47.16
+20.76%
39.05
+95.27%
20.00
+60.95%
12.43
Net Tangible Assets
7,050.99
+32.62%
5,316.84
+33.85%
3,972.28
+50.53%
2,638.80
Tangible Book Value
7,050.99
+32.62%
5,316.84
+33.85%
3,972.28
+50.53%
2,638.80
Available For Sale Securities
10.02
-32.65%
14.88
-4.17%
15.53
-10.98%
17.44
Current Provisions
402.03
+186.20%
140.47
+151.80%
55.79
+186.42%
19.48
Financial Assets Designatedas Fair Value Through Profitor Loss Total
37.13
+45.33%
25.55
+17.66%
21.71
+0.00%
21.71
Foreign Currency Translation Adjustments
138.57
+9.25%
126.83
-3.58%
131.54
+1.75%
129.28
Investmentin Financial Assets
47.15
+16.63%
40.43
+8.55%
37.24
-4.89%
39.16
Investmentsin Joint Venturesat Cost
3.38
-63.55%
9.27
-6.50%
9.91
+649.21%
1.32
Other Equity Interest
1,335.36
+27.51%
1,047.23
+35.70%
771.73
+44.18%
535.25
Unrealized Gain Loss
-64.98
-8.08%
-60.12
-1.09%
-59.47
-3.33%
-57.56
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
685.19
+928.06%
-82.75
+80.31%
-420.33
+51.28%
-862.81
Cash Flow From Continuing Operating Activities
685.19
+928.06%
-82.75
+80.31%
-420.33
+51.28%
-862.81
Net Income From Continuing Operations
1,053.81
+4966.57%
-21.65
+94.91%
-425.05
+40.99%
-720.34
Depreciation Amortization Depletion
28.10
+60.34%
17.53
-84.25%
111.31
+6.68%
104.34
Depreciation
13.24
+82.80%
7.25
+28.62%
5.63
+23.10%
4.58
Amortization Cash Flow
14.86
+44.50%
10.28
-90.27%
105.67
+5.92%
99.77
Depreciation And Amortization
28.10
+60.34%
17.53
-84.25%
111.31
+6.68%
104.34
Amortization Of Intangibles
14.86
+44.50%
10.28
-90.27%
105.67
+5.92%
99.77
Other Non Cash Items
31.63
+11518.05%
-0.28
-113.36%
2.07
—
Pension And Employee Benefit Expense
1.15
+166.44%
0.43
-24.61%
0.57
+24.84%
0.46
Stock Based Compensation
248.08
+5.49%
235.18
+0.95%
232.97
+48.37%
157.03
Operating Gains Losses
13.54
+67.67%
8.08
+62.04%
4.98
+338.73%
1.14
Unrealized Gain Loss On Investment Securities
-11.58
-202.06%
-3.83
0.00
+100.00%
-4.26
Change In Working Capital
-422.63
-29.97%
-325.17
-5.27%
-308.89
+17.79%
-375.72
Change In Receivables
-802.33
-89.63%
-423.11
-127.85%
-185.69
+16.45%
-222.26
Change In Inventory
-98.95
-3.08%
-96.00
-15.62%
-83.03
+30.39%
-119.28
Change In Prepaid Assets
-142.16
-367.17%
-30.43
+71.13%
-105.41
0.00
Change In Payables And Accrued Expense
612.33
+148.57%
246.34
+157.67%
95.60
+28957.75%
0.33
Change In Payable
612.33
+148.57%
246.34
+157.67%
95.60
+28957.75%
0.33
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
8.48
+138.61%
-21.97
+27.63%
-30.36
+12.04%
-34.51
Investing Cash Flow
984.00
+237.13%
-717.59
-332.83%
308.21
+166.83%
-461.18
Cash Flow From Continuing Investing Activities
984.00
+237.13%
-717.59
-332.83%
308.21
+166.83%
-461.18
Net PPE Purchase And Sale
-6.17
-242.31%
-1.80
-121.80%
-0.81
+2.99%
-0.84
Purchase Of PPE
-6.17
-242.31%
-1.80
-121.80%
-0.81
+2.99%
-0.84
Capital Expenditure
-111.68
-63.51%
-68.30
-55.90%
-43.81
+57.80%
-103.82
Net Investment Purchase And Sale
939.51
+224.61%
-753.94
-376.91%
272.27
+173.88%
-368.51
Purchase Of Investment
-1,448.93
+33.64%
-2,183.54
-71.70%
-1,271.73
+24.93%
-1,694.05
Sale Of Investment
2,388.45
+67.07%
1,429.60
-7.41%
1,544.00
+16.48%
1,325.54
Net Business Purchase And Sale
-6.50
+7.14%
-7.00
+46.15%
-13.00
-550.00%
-2.00
Purchase Of Business
-6.50
+7.14%
-7.00
+46.15%
-13.00
-550.00%
-2.00
Net Intangibles Purchase And Sale
-105.52
-58.67%
-66.50
-54.65%
-43.00
+58.25%
-102.99
Purchase Of Intangibles
-105.52
-58.67%
-66.50
-54.65%
-43.00
+58.25%
-102.99
Net Other Investing Changes
—
—
—
-0.00
Financing Cash Flow
233.01
-16.71%
279.76
-79.07%
1,336.73
+58.43%
843.76
Cash Flow From Continuing Financing Activities
233.01
-16.71%
279.76
-79.07%
1,336.73
+58.43%
843.76
Net Issuance Payments Of Debt
-4.11
+46.23%
-7.64
-100.95%
-3.80
+8.74%
-4.17
Repayment Of Debt
-4.11
+46.23%
-7.64
-100.95%
-3.80
+8.74%
-4.17
Long Term Debt Payments
-4.11
+46.23%
-7.64
-100.95%
-3.80
+8.74%
-4.17
Net Long Term Debt Issuance
-4.11
+46.23%
-7.64
-100.95%
-3.80
+8.74%
-4.17
Net Common Stock Issuance
0.00
0.00
-100.00%
1,196.73
+57.27%
760.95
Proceeds From Stock Option Exercised
278.38
-9.99%
309.26
+95.41%
158.26
+69.82%
93.19
Net Other Financing Charges
-41.26
-88.67%
-21.87
-51.17%
-14.47
-132.35%
-6.23
Changes In Cash
1,902.21
+465.40%
-520.58
-142.51%
1,224.61
+355.00%
-480.23
Effect Of Exchange Rate Changes
89.15
+414.71%
-28.33
-220.57%
23.49
+143.75%
-53.70
Beginning Cash Position
1,499.94
-26.79%
2,048.84
+155.87%
800.74
-40.00%
1,334.68
End Cash Position
3,491.29
+132.76%
1,499.94
-26.79%
2,048.84
+155.87%
800.74
Free Cash Flow
573.51
+479.69%
-151.05
+67.46%
-464.14
+51.98%
-966.63
Common Stock Issuance
0.00
0.00
-100.00%
1,196.73
+57.27%
760.95
Earnings Losses From Equity Investments
12.39
+62.09%
7.64
+73.29%
4.41
+551.55%
0.68
Interest Paid CFO
-0.90
-129.59%
-0.39
-85.78%
-0.21
+75.21%
-0.85
Interest Received CFI
162.67
+45.70%
111.65
+20.37%
92.75
+605.56%
13.15
Issuance Of Capital Stock
0.00
0.00
-100.00%
1,196.73
+57.27%
760.95
Taxes Refund Paid
-254.85
-3366.95%
7.80
+120.79%
-37.52
-55.40%
-24.14
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category